• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pediatr Blood Cancer . SARS-CoV-2 persistence in immunocompromised children

tetano

Editor, Senior Moderator
diatr Blood Cancer


. 2021 Aug 28;e29277.
doi: 10.1002/pbc.29277. Online ahead of print.
SARS-CoV-2 persistence in immunocompromised children


Susan A Dolan[SUP] 1 [/SUP], Jean Mulcahy Levy[SUP] 2 3 4 [/SUP], Angela Moss[SUP] 5 [/SUP], Kelly Pearce[SUP] 1 [/SUP], Molly Butler[SUP] 6 [/SUP], Sarah Jung[SUP] 6 [/SUP], Samuel R Dominguez[SUP] 7 [/SUP], Eric Mwangi[SUP] 6 [/SUP], Kelly Maloney[SUP] 2 [/SUP], Suchitra Rao[SUP] 8 [/SUP]



Affiliations

Abstract

Objectives: We evaluated the length of time immunocompromised children (ICC) remain positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), identified factors associated with viral persistence, and determined cycle threshold (C[SUB]T[/SUB] ) values of children with viral persistence as a surrogate of viral load.
Methods: We conducted a retrospective cohort study of ICC at a pediatric hospital from March 2020 to March 2021. Immunocompromised status was defined as primary, secondary, or acquired due to medical comorbidities/immunosuppressive treatment. The primary outcome was time to first of two consecutive negative SARS-CoV-2 polymerase chain reaction (PCR) tests at least 24 hours apart. Testing of sequential clinical specimens from the same subject was conducted using the Centers for Disease Control (CDC) 2019-nCoV real-time reverse transcriptase (RT)-PCR Diagnostic Panel assay. Descriptive statistics, Kaplan-Meier curve median event times and log-rank tests were used to compare outcomes between groups.
Results: Ninety-one children met inclusion criteria. Median age was 15.5 years (interquartile range [IQR] 8-18), 64% were male, 58% were White, and 43% were Hispanic/Latinx. Most (67%) were tested in outpatient settings and 58% were asymptomatic. The median time to two negative tests was 42 days (IQR 25.0-55.0), with no differences in median time by illness presentation or level of immunosuppression. Seven children had more than one sample available for repeat testing, and five of seven (71%) children had initial C[SUB]T[/SUB] values of <30 (moderate to high viral load); four children had C[SUB]T[/SUB] values of <30, 3-4 weeks later, suggesting persistent moderate to high viral loads.
Conclusions: Most ICC with SARS-CoV-2 infection had mild disease, with prolonged viral persistence >6 weeks and moderate to high viral load.

Keywords: COVID-19; SARS CoV-2; immunocompromised; pediatrics; shedding; viral persistence.
 
Back
Top Bottom